drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR-NK)
drug_description
A cellular immunotherapy in which natural killer (NK) cells are genetically engineered to express a chimeric antigen receptor (CAR) targeting CD19 on B cells; CAR engagement activates NK cytotoxic pathways (perforin/granzyme and death receptor signaling) to eliminate CD19+ B cells/plasmablasts and suppress autoantibody-driven inflammation in immune nephropathies.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Receptors, Chimeric Antigen
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Natural killer cells are genetically engineered to express a CD19-targeted chimeric antigen receptor. Upon binding CD19 on B cells, the CAR activates NK cytotoxic pathways (perforin/granzyme release and death receptor signaling), depleting CD19+ B cells/plasmablasts and reducing autoantibody-driven inflammation in immune nephropathies.
drug_name
KN5501 (anti-CD19 CAR-NK cells)
nct_id_drug_ref
NCT06469190